These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 23894391)

  • 41. Nevirapine or efavirenz combined with two nucleoside reverse transcriptase inhibitors compared to HAART: a meta-analysis of randomized clinical trials.
    Torre D; Tambini R; Speranza F
    HIV Clin Trials; 2001; 2(2):113-21. PubMed ID: 11590519
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nevirapine-based regimens in HIV-infected antiretroviral-naive patients: systematic review and meta-analysis of randomized controlled trials.
    Kawalec P; Kryst J; Mikrut A; Pilc A
    PLoS One; 2013; 8(10):e76587. PubMed ID: 24116123
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir.
    Abgrall S; Yeni PG; Bouchaud O; Costagliola D;
    AIDS; 2006 Oct; 20(16):2099-106. PubMed ID: 17053356
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Nevirapine versus efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and tuberculosis infections in India: a pilot study.
    Sinha S; Raghunandan P; Chandrashekhar R; Sharma SK; Kumar S; Dhooria S; Ekka M; Velpandian T; Ranjan S; Ahmad H; Samantaray JC; Venkatesh S; Rewari BB; Khan NH; Pandey RM
    BMC Infect Dis; 2013 Oct; 13():482. PubMed ID: 24134449
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Outcome of artemether-lumefantrine treatment for uncomplicated malaria in HIV-infected adult patients on anti-retroviral therapy.
    Maganda BA; Minzi OM; Kamuhabwa AA; Ngasala B; Sasi PG
    Malar J; 2014 May; 13():205. PubMed ID: 24885714
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Occult HIV-1 drug resistance to thymidine analogues following failure of first-line tenofovir combined with a cytosine analogue and nevirapine or efavirenz in sub Saharan Africa: a retrospective multi-centre cohort study.
    Gregson J; Kaleebu P; Marconi VC; van Vuuren C; Ndembi N; Hamers RL; Kanki P; Hoffmann CJ; Lockman S; Pillay D; de Oliveira T; Clumeck N; Hunt G; Kerschberger B; Shafer RW; Yang C; Raizes E; Kantor R; Gupta RK
    Lancet Infect Dis; 2017 Mar; 17(3):296-304. PubMed ID: 27914856
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Concomitant use of nonnucleoside analogue reverse transcriptase inhibitors and rifampicin in TB/HIV type 1-coinfected patients.
    Sathia L; Obiorah I; Taylor G; Kon O; O'Donoghue M; Gibbins S; Walsh J; Winston A
    AIDS Res Hum Retroviruses; 2008 Jul; 24(7):897-901. PubMed ID: 18671475
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Efavirenz Plus Two Nucleoside Reverse Transcriptase Inhibitors As Initial Antiretroviral Therapy for People with HIV: A Systematic Review.
    Rutherford GW; Horvath H
    PLoS One; 2016; 11(10):e0162775. PubMed ID: 27736859
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy.
    Leth FV; Kappelhoff BS; Johnson D; Losso MH; Boron-Kaczmarska A; Saag MS; Livrozet JM; Hall DB; Leith J; Huitema AD; Wit FW; Beijnen JH; Lange JM;
    AIDS Res Hum Retroviruses; 2006 Mar; 22(3):232-9. PubMed ID: 16545009
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The nucleoside backbone affects durability of efavirenz- or nevirapine-based highly active antiretroviral therapy in antiretroviral-naive individuals.
    Annan NT; Nelson M; Mandalia S; Bower M; Gazzard BG; Stebbing J
    J Acquir Immune Defic Syndr; 2009 Jun; 51(2):140-6. PubMed ID: 19352201
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study.
    Matthews GV; Sabin CA; Mandalia S; Lampe F; Phillips AN; Nelson MR; Bower M; Johnson MA; Gazzard BG
    AIDS; 2002 Jan; 16(1):53-61. PubMed ID: 11741163
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The effect of malnutrition on the pharmacokinetics and virologic outcomes of lopinavir, efavirenz and nevirapine in food insecure HIV-infected children in Tororo, Uganda.
    Bartelink IH; Savic RM; Dorsey G; Ruel T; Gingrich D; Scherpbier HJ; Capparelli E; Jullien V; Young SL; Achan J; Plenty A; Charlebois E; Kamya M; Havlir D; Aweeka F
    Pediatr Infect Dis J; 2015 Mar; 34(3):e63-70. PubMed ID: 25742090
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Use of non-nucleoside analogues together with rifampin in HIV patients with tuberculosis.
    Villar J; Sánchez P; González A; Sorli L; Montero MM; Guelar A; Solé E; López JL; Knobel H
    HIV Clin Trials; 2011; 12(3):171-4. PubMed ID: 21684857
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Role of non-nucleoside reverse transcriptase inhibitors in treating HIV-infected children.
    Penazzato M; Giaquinto C
    Drugs; 2011 Nov; 71(16):2131-49. PubMed ID: 22035514
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and durability of nevirapine in antiretroviral drug näive patients.
    Lange JM
    J Acquir Immune Defic Syndr; 2003 Sep; 34 Suppl 1():S40-52. PubMed ID: 14562857
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Plasma HIV-1 RNA decline within the first two weeks of treatment is comparable for nevirapine, efavirenz, or both drugs combined and is not predictive of long-term virologic efficacy: A 2NN substudy.
    van Leth F; Huisamen CB; Badaro R; Vandercam B; de Wet J; Montaner JS; Hall DB; Wit FW; Lange JM;
    J Acquir Immune Defic Syndr; 2005 Mar; 38(3):296-300. PubMed ID: 15735447
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes.
    Chiesa E; Bini T; Adorni F; Capetti A; Rizzardini G; Faggion I; Mussini C; Sollima S; Melzi S; Bongiovanni M; Tordato F; Cicconi P; Castelnuovo B; Rusconi S; d'Arminio Monforte A
    Antivir Ther; 2003 Feb; 8(1):27-35. PubMed ID: 12713061
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment.
    Maganda BA; Ngaimisi E; Kamuhabwa AA; Aklillu E; Minzi OM
    Malar J; 2015 Apr; 14():179. PubMed ID: 25906774
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the Western Cape, South Africa.
    van Zyl GU; van der Merwe L; Claassen M; Zeier M; Preiser W
    J Med Virol; 2011 Oct; 83(10):1764-9. PubMed ID: 21837793
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Lack of effect from a previous single dose of nevirapine on virologic and immunologic responses after 6 months of antiretroviral regimens containing either efavirenz or lopinavir-ritonavir.
    Dlamini JN; Hu Z; Somaroo H; Highbarger HC; Follmann DA; Dewar RL; Pau AK
    Pharmacotherapy; 2011 Feb; 31(2):158-63. PubMed ID: 21275494
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.